Navigation Links
Warner Chilcott Seeks to Refinance its Existing Credit Agreement
Date:3/2/2011

DUBLIN, March 2, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that certain of its subsidiaries are seeking to refinance the Company's existing credit agreement, dated as of October 30, 2009, as amended (the "Existing Credit Agreement"), by entering into a new credit agreement expected to close in mid-March 2011.  The refinancing is expected to have the effect of extending the maturity profile, reducing certain LIBOR floors and/or interest margins and potentially modifying certain other provisions of the Existing Credit Agreement. The Company can offer no assurance that the refinancing will be consummated.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness, including increases in the LIBOR rates on our variable-rate indebtedness above the applicable floor amounts; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying any of our manufacturing facilities that produce our products or production or regulatory problems with either our own manufacturing facilities or third party manufacturers or API suppliers upon whom we may rely for some of our products; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities, such as the recently enacted excise tax legislation in Puerto Rico; our ability to realize the anticipated opportunities from the PGP Acquisition; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2010, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2010
2. Warner Chilcott to Present at the Citi 2011 Global Health Care Conference
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
4. Warner Chilcott to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
6. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
7. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
8. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
9. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
10. Warner Chilcott Announces FDA Approval of Next Generation Actonel
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year ... be $394.9 billion. The consequences of rapid innovation and growth are often neglected ... technology, it is every business and individual’s job to give something back to the ...
(Date:4/21/2017)... ... 2017 , ... An April 10 article in the Daily Mail ... a great deal about prehistoric ice-age dental practitioners and their primitive and, no doubt, ... remove decayed dental matter, and that teeth were then filled with bitumen, a substance ...
(Date:4/21/2017)... SALT LAKE CITY, Utah (PRWEB) , ... April ... ... leading provider of wilderness therapy treatment for adolescents and young adults, has kicked ... Thursday, April 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community ... System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition of ... DeVaro was honored with the award at The Beryl Institute’s annual Patient Experience ...
(Date:4/21/2017)... ... 21, 2017 , ... Alive for Wellness is a group of ... health struggles. The Alive team uses advanced behavioral sciences treatment modalities to accomplish ... a mental health struggle is based on 10 modalities of treatment that ...
Breaking Medicine News(10 mins):